Biomarker; Research

3A - Emerging Model Systems for Validation of Targetable Biomarkers and Drug Screening
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5

Tuesday, October 10
10:15 AM - 11:45 AM

Validation of companion therapeutic biomarkers for personalized therapy has suffered from the lack of appropriate model systems to test biomarker-guided therapies. Conventional cell lines have been used extensively with little success. Conversely, genetically engineered animal models rarely recapitulate human cancer in a personalized manner, while models based on patient-derived xenografts in immunocompromised mice are notoriously slow, cumbersome and expensive. Three-dimensional (3D) tissue modeling in vitro and live-tissue sensitivity assays, to be discussed in this session, are promising new mechanisms to fill the gap and to provide reliable, sensitive, and affordable characterization of tumor samples for biomarker validation and response to treatment.

Mitesh Borad, MD

1.Rob Vries, PhD. – world leading center for organoid research Managing Director Hubrecht Organoid Technology (HUB)
2.Ross Cagan, PhD – intriguing drosophila model for real-time patient drug screening Professor Icahn School of Medicine at Mount Sinai
3.Panos Anastasiadis, PhD – Mayo approaches to model systems (3D canceroids, PDX, other)

Learning Objectives:

Mitesh J. Borad

Assistant Professor of Medicine, College of Medicine, Consultant
Mayo Clinic


Send Email for Mitesh Borad

Ross Cagan

Icahn School of Medicine at Mount Sinai

Ross L. Cagan, PhD, is currently (2007-present) Professor in the Department of Developmental and Regenerative Biology, Director of the Center for Personalized Cancer Therapeutics, and Senior Editor of the journal Disease Models and Mechanisms. He was Co-Founder and board member of the biotechnology company Medros Inc.

Dr. Cagan is an expert in utilizing Drosophila to explore cell-cell signaling and epithelial patterning. Moving to Mount Sinai to develop his interest in translational science, Dr. Cagan has been a pioneer in the use of Drosophila to identify therapeutic leads for cancer (breast, lung, thyroid, colorectal), diabetes, and inherited genetic diseases. Taking advantage of a century of powerful genetic tools, his laboratory has developed complex, multigenic disease models designed to model whole body complexity of human disease. This approach helped promote the first FDA-approved chemotherapeutic for Medullary Thyroid Carcinoma. His laboratory has developed a novel platform that combines genetics with medicinal and computational chemistry to develop novel drugs that emphasize rational polypharmacology. Leveraging these new technologies, Dr. Cagan leads the Center for Personalized Cancer Therapeutics team that develops and treats thyroid and colorectal cancer patients through a personalized fly-to-bedside, open label clinical trial.Â


Send Email for Ross Cagan

Panagiotis Anastasiadis

Professor of Cancer Biology, Associate Professor of Biochemistry and Molecular Biology
Mayo Clinic

Panos Z. Anastasiadis, PhD, is professor of cancer biology in the Mayo Clinic College of Medicine, and consultant in the Mayo Clinic Cancer Center. Dr. Anastasiadis currently serves as chair of Mayo Clinic's enterprise-wide Department of Cancer Biology. He is also co-director of the Cell Biology program of the Mayo Clinic Cancer Center, member of the executive committee for the Mayo Clinic Center for Biomedical Discovery, and member of the executive committee for biomarker discovery at the Mayo Clinic Center for Individualized Medicine.

His research interests are focused on signaling events that regulate cell-cell adhesion or cell migration/invasion and transformed cell growth. His expertise includes cell-cell adhesion signaling, regulation of Rho GTPases during cell adhesion and/or migration, as well as the establishment of cell polarity in both adherent and migrating cells. Additionally, his lab uses organotypic 3D cultures, genomics, proteomics and antibody-based methodologies as a means of identifying oncogenic pathways that are activated in individual patient's tumors and can be targeted for therapy on an individualized basis. He has served as a member of the Tumor Progression and Metastasis NIH study section, and recently as Chair of the Neural Regulation of Cancer NIH study section.


Send Email for Panagiotis Anastasiadis

Farzin Pourfarzad

Group leader scientist
Hubrecht Organoid Technology

Farzin Pourfarzad, PhD, performed his PhD research in the lab of Prof. Frank Grosveld on globin gene regulation in adult hematopoetic stem cells. He received his PhD in 2010 in molecular genetics from Erasmus Medical Centre, The Netherlands. Subsequently, he moved to the Dutch national blood bank, Sanquin, to do his postdoctoral research. He worked on epigenetic profiling of myeloid progenitor cells during differentiation within BLUEPRINT consortium coordinated by Henk Stunnenberg. He is now group leader at Hubrecht Organoid Technology (HUB) founded by Prof. Hans Clevers and leads organoid R&D projects.


Send Email for Farzin Pourfarzad


3A - Emerging Model Systems for Validation of Targetable Biomarkers and Drug Screening
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Emerging Model Systems for Validation of Targetable Biomarkers and Drug Screening
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5